Evolus (EOLS)
(Delayed Data from NSDQ)
$11.58 USD
+0.15 (1.31%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $11.57 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
EOLS 11.58 +0.15(1.31%)
Will EOLS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for EOLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EOLS
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
EOLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Other News for EOLS
Evolus Shareholders Approve ESPP and Director Elections
Evolus’s Evolysse Line Poised for Growth: A Promising Buy Recommendation
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rare Stock Picks In May 2024 - From 29 Discerning Analysts
Evolus: Chiseling Away At The Aesthetic Market